Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
In human volunteers intranasal administration of oxytocin significantly increases
parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease
with high cardiovascular risk factors, yet this disease remains very poorly treated.
This proposal, based on the current literature and new basic science results detailed above
on the role of oxytocin in cardiovascular control, will test if oxytocin administration
improves adverse cardiovascular events during the recurrent nocturnal apneas in patients with
OSA. This project will lay the groundwork and provide preliminary data to obtain NIH funding
to test this important hypotheses more thoroughly and in larger clinical trials.
This study will explore if intranasal oxytocin has any positive cardiovascular benefits in
patients with sleep apnea.